Use of HMG-CoA reductase inhibitors for the treatment of cisplatin resistant cancer

摘要

The present invention provides a means for treating cisplatin-resistant cancers. Specifically, the present invention provides a cisplatin-resistant cancer cytotoxic agent or the like, which contains an HMG-CoA reductase inhibitor. The present invention enables cisplatin-resistant cancers to be effectively destroyed, thereby enabling cisplatin-resistant cancers to be treated.